


# Perspectives: Potential Therapeutic Options for SARS-CoV-2 Patients Based on Feline Infectious Peritonitis Strategies: Central Nervous System Invasion and Drug Coverage

Mark Olsen , Sarah Elizabeth Cook , Vanthida Huang , Niels Pedersen , Brian G. Murphy

PII: S0924-8579(20)30121-7
DOI: https://doi.org/10.1016/j.ijantimicag.2020.105964
Reference: ANTAGE 105964

To appear in: *International Journal of Antimicrobial Agents*

Please cite this article as: Mark Olsen , Sarah Elizabeth Cook , Vanthida Huang , Niels Pedersen , Brian G. Murphy , Perspectives: Potential Therapeutic Options for SARS-CoV-2 Patients Based on Feline Infectious Peritonitis Strategies: Central Nervous System Invasion and Drug Coverage, *International Journal of Antimicrobial Agents* (2020), doi: https://doi.org/10.1016/j.ijantimicag.2020.105964

**Perspectives: Potential Therapeutic Options for SARS-CoV-2 Patients Based on Feline Infectious Peritonitis Strategies: Central Nervous System Invasion and Drug Coverage**

Mark Olsen*[1], Sarah Elizabeth Cook[2], Vanthida Huang[3], Niels Pedersen[4], Brian G Murphy*[2]

[1]Department of Pharmaceutical Sciences, College of Pharmacy – Glendale, Midwestern University19555 N. 59th Avenue, Glendale AZ 85308 USA

[2]Department of Pathology, Microbiology & Immunology, School of Veterinary Medicine, University of California, One Shields Avenue, Davis CA 95616 USA

[3]Department of Pharmacy Practice, College of Pharmacy – Glendale, Midwestern University, 19555 N. 59th Avenue, Glendale AZ 85308 USA

[4]Center for Companion Animal Health, School of Veterinary Medicine, University of California, One Shields Avenue Davis, CA 95616 USA

*Contributed equally

**Corresponding Author and Requests for Re-prints**

Mark Olsen

College of Pharmacy – Glendale, Midwestern University

19555 N. 59th Ave.

Glendale, AZ 85308

Phone: (623)572-3568

FAX: (623)572-3565

Email: molsen@midwestern.edu

Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (SARS-CoV-2) infections are continuing to increase globally, and clinicians at hospitals are currently preparing lists of Food and Drug Administration (FDA) approved therapies as options for the treatment of SARS-CoV-2. For several years, we have been investigating anti-coronavirus therapies directed at feline infectious peritonitis (FIP) [1, 2], a disease with a nearly 100% mortality in felines caused by a coronavirus. Feline enteric coronavirus (FEC), commonly found in many felines that are asymptomatic, mutates into the virulent and lethal FIP coronavirus [3]. We believe that our experimental observations for treatment of FIP may be relevant and translational for recent *in vitro* results of SARS-CoV-2[4] in the absence of extensive laboratory and human clinical trials. A FIP coronavirus protease inhibitor, GC376, was successful in the treatment of a subset of felines with FIP; however, in cases where there was neurological involvement the protease inhibitor was unable to prevent progression of central nervous system (CNS) disease resulting in neurological FIP and subsequent euthanasia [5]. A polymerase inhibitor, GS-441524, has already demonstrated significant activity in a feline clinical trial against FIP [1], but the treatment of neurological involvement has yet to be demonstrated. Remdesivir, which is a prodrug for GS-441524, shows great promise for the treatment of SARS-CoV-2 [6], but is not currently approved by the FDA, and is only available in an intravenous (IV) formulation. There is an urgent need for anti-SARS-CoV-2 therapies that are already FDA approved, orally bioavailable, appropriate for organs that express the SARS-CoV-2 target angiotensin-converting enzyme 2 (ACE2) and may also complement or synergize with remdesivir upon approval. While the detailed experimental results will be communicated elsewhere (unpublished data from BGM laboratory), we believe our observations could support clinicians regarding treatment options in addition to supportive care.

Severe Acute Respiratory Syndrome coronavirus 1 (SARS-CoV-1) and SARS-CoV-2 both target ACE2 [7], which is expressed in the lungs, heart, gastrointestinal tract, and CNS [8] in humans. SARS-CoV-1 is known to penetrate the CNS through the olfactory nerve and olfactory bulb route [9], like other

coronaviruses [10]. COVID-19 patients often experience anosmia, the loss of smell, suggesting this route may also occur following SARS-CoV-2 infection. Almost all beta-coronaviruses penetrate the CNS [10], and SARS-CoV-1 and SARS-CoV-2 share the same ACE2 receptor. It is also reasonable to believe that the massive infection of the brainstem in experimental animals following SARS-CoV-1 nasal exposure [9] may also occur with SARS-CoV-2 which could contribute to sudden respiratory failure as observed with patients [10]. It is not clear if SARS-CoV-2 CNS penetration may also occur in patients with recent damage to the blood-brain barrier (BBB) following a stroke or other brain insult. As we have shown in felines, the implications of CNS penetration emphasize the need for a multi-pronged organ appropriate strategy that will suppress SARS-CoV-2 in both the periphery and brain.

We have found that nelfinavir and amodiaquine have anti-FIP activity *in vitro* comparable to chloroquine, and superior to ribavirin, penciclovir, favipiravir, and nafamostat against SARS-CoV-2 [4]. Amodiaquine, like chloroquine and hydroxychloroquine, is a CNS penetrating 4-aminoquinoline anti-malarial drug that inhibits the formation of hemozoin in the parasite but has been withdrawn from the United States (US) market although it is still available in other countries. Amodiaquine is known to possess some antiviral activity, and derivatives have been explored for inhibition of Ebola virus infection [11]. Pharmacogenomics has revealed that the presence of the CYP4502C8*2 allele is an important contributor to amodiaquine toxicity [12]. Appropriate monitoring parameters include complete blood counts with differential and liver function tests because serious adverse events are agranulocytosis and hepatotoxicity with mild adverse events being nausea, emesis, and pruritus. Amodiaquine/artesunate is available for the treatment of malaria; it is cost-effective and accessible outside of the US. This is the third observation of a 4-aminoquinoline having activity against a coronavirus, and compliments clinical observations from China [13, 14]. Secondly, the 4-aminoquinolines are well known to penetrate the BBB, and have been investigated for a broad-spectrum antiviral activity for a variety of viral infections, including Zika [15], Dengue [16] and Ebola [17] viruses. It also may have utility for those patients

suffering from SARS-CoV-2 in the brainstem. The antiviral mechanisms of action of chloroquine may include altering endosomal RNA release [15], altering autophagy-dependent viral replication [15], and inhibiting ACE2 glycosylation [18].

Nelfinavir is an older anti-human immunodeficiency virus (HIV) protease inhibitor capable of inhibiting HIV-1, and to a lesser extent, HIV-2 proteases [19], but is no longer the first treatment of choice. However, it has a spectrum of activity that includes both SARS-CoV-1 [20] and FIP coronavirus [21], is orally bioavailable, and can achieve a plasma concentration of 7.3 mg/L at 3000 mg twice daily [22]. Other protease inhibitors, including the combination of lopinavir and ritonavir, were utilized for the treatment of SARS-CoV-1 [23], and have been used in Singapore [24] and China [25] for the treatment of SARS-CoV-2. However, there have been challenges associated with toxicity at the prescribed doses [24] and efficacy as a monotherapy [25]. The hypothesis for using older anti-retroviral agents with higher toxicity, but a potentially broader antiviral spectrum of activity is not novel. However, the experimental observation of nelfinavir suppressing FIP coronavirus [21] provides additional data to consider nelfinavir as an option for SARS-CoV-2. Appropriate monitoring parameters for nelfinavir include echocardiogram for QT interval prolongation and Torsades de pointes as well as diarrhea, fatigue (10-20%), lipodystrophy, and hyperglycemia.

In summary, these observations of *in vitro* activity against FIP coronavirus are not a substitute for clinical data and trial but may provide further guidance for off-label therapeutic strategies. The mutation of FEC into FIP coronavirus may provide a paradigm for considering the relationship between different strains of SARS-CoV-2. Nelfinavir, chloroquine, and hydroxychloroquine are FDA approved, orally bioavailable, and commercially available and have at least *in vitro* data against either SARS-CoV-1 or SARS-CoV-2. Nelfinavir may be an alternative to lopinavir/ritonavir. Amodiaquine, hydroxychloroquine, and chloroquine all possess CNS penetration activity. Amodiaquine may be an alternative to chloroquine in

territories where it is available. These agents can offer clinicians another therapeutic strategy beyond supportive care as monotherapy or in combination.

**Declarations**

**Funding:** MO acknowledges funding from Midwestern University.

BGM acknowledges funding from Winn Feline Foundation and the University of California, Davis Center for Companion Animal Health through gifts specified for FIP research by numerous individual donors and organizations (SOCK FIP, Davis, CA) and Foundations (Philip Raskin Fund, Kansas City, KS).

**Competing Interests:** The authors declare no conflicts of interest.

**Ethical Approval**: Not required

**References**

1. Murphy BG, Perron M, Murakami E, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Veterinary microbiology 2018; 219:226-33.
2. Pedersen NC, Eckstrand C, Liu H, Leutenegger C, Murphy B. Levels of feline infectious peritonitis virus in blood, effusions, and various tissues and the role of lymphopenia in disease outcome following experimental infection. Veterinary microbiology 2015; 175:157-66.
3. Licitra BN, Millet JK, Regan AD, et al. Mutation in spike protein cleavage site and pathogenesis of feline coronavirus. Emerging infectious diseases 2013; 19:1066-73.
4. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research 2020; 30:269-71.
5. Pedersen NC, Kim Y, Liu H, et al. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. Journal of feline medicine and surgery 2018; 20:378-92.
6. Ko WC, Rolain JM, Lee NY, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International journal of antimicrobial agents 2020:105933.
7. Qiu Y, Zhao YB, Wang Q, et al. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2. Microbes and infection 2020.
8. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of pathology 2004; 203:631-7.
9. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. Journal of virology 2008; 82:7264-75.
10. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients. Journal of medical virology 2020.
11. Sakurai Y, Sakakibara N, Toyama M, Baba M, Davey RA. Novel amodiaquine derivatives potently inhibit Ebola virus infection. Antiviral research 2018; 160:175-82.
12. Gil JP, Gil Berglund E. CYP2C8 and antimalaria drug efficacy. Pharmacogenomics 2007; 8:187-98.
13. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020.
14. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends 2020.
15. Zhang S, Yi C, Li C, et al. Chloroquine inhibits endosomal viral RNA release and autophagy-dependent viral replication and effectively prevents maternal to fetal transmission of Zika virus. Antiviral research 2019; 169:104547.
16. Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacology research & perspectives 2017; 5:e00293.
17. Du X, Zuo X, Meng F, et al. Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. Biochemical and biophysical research communications 2020; 522:862-8.
18. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal 2005; 2:69.
19. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antiviral therapy 2004; 9:57-65.

20. Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochemical and biophysical research communications 2004; 318:719-25.
21. Hsieh LE, Lin CN, Su BL, et al. Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus. Antiviral research 2010; 88:25-30.
22. Pan J, Mott M, Xi B, et al. Phase I study of nelfinavir in liposarcoma. Cancer chemotherapy and pharmacology 2012; 70:791-9.
23. Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus-A Possible Reference for Coronavirus Disease-19 Treatment Option. Journal of medical virology 2020.
24. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. Jama 2020.
25. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England journal of medicine 2020.